cyrilzakka/clinical-trials huggingface dataset:
Saphenous Vein as Y-composite Versus Aortocoronary Conduit for CABG

Left internal thoracic artery (LITA) has been acknowledged as the first graft of choice for coronary artery bypass grafting (CABG). However, it is still not conclusive which one is the best second graft of choice among right internal thoracic artery, radial artery, right gastroepiploic artery, saphenous vein, and etc., as well as its configuration for CABG.

In our institution, saphenous vein has been primarily used for the second graft and we have harvested it with 'No touch technique'. We have been demonstrated the excellent long-term patency of this 'No touch saphenous vein' in many studies. However, it is still unknown which configuration is the better strategy for the saphenous vein as a Y-composite graft based on the left internal thoracic artery versus an aortocoronary conduit. Thus, we aimed to evaluate morphologic change of saphenous vein graft by 1-year intravascular ultrasound (IVUS) study and angiographic patency results between Y-composite graft and aortocoronary conduit.

The enrolled patient underwent routine sternotomy, and left internal thoracic artery (LITA) and saphenous vein (SV) are harvested. After harvest, the patient is randomized to Y-composite group or aortocoronary group.

For Y-composite group, SV is anastomosed to LITA as Y-composite fashion. Then, LITA is anastomosed to left anterior descending artery. SV is anastomosed to the rest of the target vessels with sequential anastomosis technique (e.g. diagonal branch, obtuse marginal branch, posterolateral branch and posterior descending artery).

For aortocoronary group, LITA is anastomosed to left anterior descending artery. Then, SV is anastomosed to ascending aorta using proximal anastomosis assist device without clamping the aorta. SV is anastomosed to the rest of the target vessels with sequential anastomosis technique (e.g. diagonal branch, obtuse marginal branch, posterolateral branch and posteriori descending artery).

At 1-year follow-up, coronary angiography is performed to evaluate the patency of the saphenous vein graft. Clinical outcomes are also evaluated.

Eligibility Criteria:
Inclusion Criteria:

* A patient who is going to receive coronary artery bypass grafting
* Older than 19 years
* Coronary artery bypass grafting is going to be performed with left internal thoracic artery and saphenous vein graft

Exclusion Criteria:

* Other concomitant procedures (e.g. valve or aorta surgery) is planned
* Patients with severe comorbidities which limit the life expectancy of them below 1 year (e.g. terminal cancer)
* Patients whose left internal thoracic artery or saphenous vein is not available due to the low quality, severe injury, or absence of the graft
* Patients whose ascending aorta is not suitable to aortocoronary anastomosis (e.g. ascending aorta aneurysm, porcelain aorta)
* Emergency operation
* Patients who have connective tissue disease
* Reoperative coronary artery bypass grafting
Initial Positioning of Left Sided Double Lumen Endobronchial Tubes Using Peak Inspiratory Pressures Difference Between Two Lungs

The purpose of this study is to investigate a performance of initial positioning of left sided double lumen endobronchial tubes using peak inspiratory pressures difference between two lungs.

If both lungs have relatively equal volumes and the double lumen tube is in a satisfactory position, peak inspiratory pressure between two lungs is similar or equal when each lumen is sequentially clamped while ventilating each lung with the same tidal volume. We are going to investigate a performance of this method by fiberoptic bronchoscopy view and depth of double lumen tube, and compare with an conventional auscultation method.

Eligibility Criteria:
Inclusion Criteria:

* ASA physical status class I, II
* Use of double lumen tube
* Normal preoperative pulmonary function study

Exclusion Criteria:

* COPD
* Restrictive lung disease
* CAOD
* Unstable hemodynamic status
* Peak inspiratory pressure \> 30 mm Hg (Two lung ventilation)
Efficacy of Intracoronary Infusion of Different Medicine in STEMI Patients With CSFP

The study intends to evaluate the efficacy of different medicine delivering by targeted perfusion catheter in coronary administration on coronary blood flow in STEMI patients with CSFP.

The goal of STEMI therapy is to successfully restore epicardial blood flow. PCI has been documented as being the most effective method for restoration of epicardial blood flow. However, stenting does not necessarily equate to epicardial blood flow; not every patient achieves TIMI 3 flow after successful PCI.

Currently, there are two main types of interventions to improve epicardial blood flow. One is the mechanical method, which included thrombus aspiration catheter and the distal protective devices. It has been confirmed that the mechanical method can effectively improve epicardial and myocardial perfusion in patient with part of large vessels and high burden thrombus. But for patients with small vessels and no obvious visual thrombus, the efficacy is not significant.

The other intervention is medicine which included GP IIb/IIIa receptor antagonist, adenosine, sodium nitroprusside, verapamil etc. Part of the drugs have some effect but the overall clinical efficacy is still not satisfied.

The study intends to use targeted perfusion catheter to deliver drug to the distal targeted blood vessels. TFG and cTFC are applied to evaluate the efficacy of treatment with Alprostadil or Nitroglycerin on coronary blood flow in STEMI patients with CSFP.

Eligibility Criteria:
Inclusion Criteria:

Patents with myocardial infarction who have symptom onset within 12h before randomization; ECG: ≥2 mm ST-segment elevation in 2 contiguous precordial leads or ≥1 mm ST-segment elevation in 2 contiguous extremity leads ; Corrected TIMI frame counted (cTFC) measured from the final angiographic imaging after PCI exceeding 40 frames; Signed informed consent form prior to trial participation.

Exclusion Criteria:

Coronary artery bypass surgery (CABG) history; Failed in stents implanting; Severe heart failure; Cardiogenic shock.
The Use of Low Level Laser Therapy for Wound Healing in Leprosy Patients

Neuropathic ulcers are common sequelae of leprosy. The objectives of this study are to analyze the clinic-epidemiological characteristics of patients attended at one specialized dressing service from a leprosy-endemic region of the Brazilian Amazon and to evaluate the effect of Low Level Laser Therapy on wound healing of these patients.


Eligibility Criteria:
Inclusion Criteria:

* presented with neuropathic ulcer
* attended at least 3 weekly appointments at the dressing service of UREMC
* completed specific multi-drug therapy for M. leprae
* gave written informed consent to participate in the study

Exclusion Criteria:

* clinically detectable infection in the ulcer
* use of drugs, like corticosteroids that could interfere with the wound healing process
* use of special dressings like hydrocolloid, calcium alginate, activated carbon or any kind of therapeutic procedure different from that used routinely for both groups of study
* non-attendance to therapeutic program (six sequential times or nine intercalated)
* pregnancy
* discomfort during treatment procedure
Virtual and Video Counseling Versus In-Office Counseling for Laparoscopic Hysterectomy

Compare preparedness for total laparoscopic hysterectomies between patients who undergo virtual visits and those who undergo in-office visits for pre-operative counseling.

The proposed research study looks to evaluate the effectiveness of combination of video counseling and virtual visits for pre-operative counseling as compared to in-office pre-operative counseling visits ahead of total laparoscopic hysterectomy surgery. Comparison of the two cohorts will be based on responses to surveys regarding patient preparedness on the day of surgery and information obtained from the electronic medical record.

Eligibility Criteria:
Inclusion Criteria:

* Patient undergoing laparoscopic hysterectomy for benign gynecologic etiologies.
* Age of 20 years or older
* Understand English language (written and spoken) without difficulty

Exclusion Criteria:

* Age less than 20 years old
* Diagnosis of malignancy
* No access to technology that would allow for watching counseling video and/or completion of virtual visit
A Study to Evaluate Safety, Tolerability, Plasma Drug Levels, and Cognitive Response Following Multiple Doses of a Drug in Healthy Elderly Participants.

Evaluate the safety and tolerability of PF-04447943 after administration of multiple doses in healthy elderly participants. Evaluate plasma drug levels and effects on cognition.


Eligibility Criteria:
Inclusion Criteria:

* Healthy male and/or female subjects.
* Subjects must be in reasonably good health as determined by the investigator based on medical history, full physical examination (including blood pressure and pulse rate measurement), 12 lead ECG and clinical laboratory tests.
* Subjects with mild, chronic, stable disease (eg, controlled hypertension, non-insulin dependent diabetes, osteoarthritis may be enrolled if deemed medically prudent by the investigator.
* Subjects taking daily prescription or non-prescription medications for management of acceptable chronic medical conditions must be on a stable dose.
* Body Mass Index (BMI) between 18 to 30 kg/m2, inclusive; and a total body weight \>50 kg (110 lbs).
* Creatinine clearance greater than 30 mL/min using the Cockcroft-Gault method.

Exclusion Criteria:

* Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, immunologic, or allergic disease.
* Use of tobacco or any form of nicotine in the past 6 months.
* Greater than 7 drinks of alcohol per week for women, and greater than 14 drinks of alcohol per week for men.
ANAL PRECANCEROUS LESIONS IN HIGH-RISK PATIENTS.

HIV-positive patients, women with a history of genital neoplasia and patients under pharmacologically immunosuppression (e.g. transplanted recipients, Crohn´s disease and Lupus) are a high-risk population for anal human-papillomavirus infection and associated complications, like anal precancerous lesions and anal squamous cell carcinoma. There is a lack of information on the prevalence of anal precancerous detected by routine colonoscopy in this population, by evaluating the squamocolumnar junction (the most susceptible area for lesions) during this procedure. Given, the increasing incidence rates of anal squamous cell carcinoma expected for the next two decades and the increase number of at-risk patients, the possible benefit of routine endoscopy in the diagnosis of anal precancerous lesions needs to be further explored.

Procedures in all patients:

1. Digital anorectal evaluation
2. Colonoscopy with retroflection and visualization of the anal squamocolumnar junction
3. After identification of this area 5% acetic acid will be applied.
4. Visualization under NBI/BLI.
5. Biopsies of all the suspected lesions of anal high-grade squamous lesions (HSIL).

Eligibility Criteria:
Inclusion Criteria:

1. HIV-positive patients
2. Solid transplanted recipients
3. Crohn's disease patients under immunosuppression: steroids, thiopurines, biologics
4. Patients with lupus under immunosuppression
5. Women with a previous history of genital neoplasia (high-grade lesions or cancer) in the cervix, vagina or vulva.

Exclusion Criteria:

1. Previous anal/perianal cancer history
2. Previous known history of anal/perianal intraepithelial neoplasia
3. Pelvic radiation
Application of Deep Learning to Jointly Assess Embryo Development to Improve Pregnancy Outcome of Embryo Transfer

Aim of this research is to apply the deep learning automation based on Time-lapse imaging to jointly assess embryo development，so that it can ensure the consistency of embryo evaluation and improve the accuracy of evaluation.

This study is an observational prospective study after a retrospective analysis. It is a single-center study without randomization or blindness. In the early stage, 1000 patients are collected from three periods of embryo culture through Time-lapse to establish an automated joint evaluation system for the whole process of embryo development. At the later stage, the patients are divided into two groups: Time-Lapse imaging (TLI) +Artificial Intelligence(AI) assessment group and morphological assessment group. 100 patients with Day 5 single blastocyst transplantation are carried out to follow up the pregnancy outcome.

Eligibility Criteria:
Inclusion Criteria:

* (1) Age \< 40 years old; (2) Routine IVF cycles; (3) Period number ≤ 2; (4) The number of ova collected is 5-15; (5) BMI: 18-25 kg/m 2, follicle stimulating hormone(FSH) ≤ 12 IU/L on the third day; (6) Patients with more than 3 high-quality embryos on Day3 and performed single blastocyst transplantation on day 5. (7) Patient without endometrial factors.

Exclusion Criteria:

* (1) Preimplantation Genetic Testing(PGT) is needed due to male infertility, ovulation cycle and chromosome abnormalities; (2) there are systemic diseases of clinical significance; (3) Pictures of blastocysts are not formed or available; (4) Incomplete or unclear image collection in prokaryotic, mitotic and blastocyst phases affected AI evaluation.
Cerebral Blood Flow Velocity Changes During Laparoscopic Surgery

Little is known about how implementation of pneumoperitoneum contributes to cerebral blood flow in pediatrics. We investigated this question in patients undergoing laparoscopic surgery, hypothesizing that cardiorespiratory changes during this procedure would reduce cerebral perfusion.


Eligibility Criteria:
Inclusion Criteria:

* pediatric patients undergoing laparoscopic surgery

Exclusion Criteria:

-
Improving the Well-being of Caregivers of Cystic Fibrosis Patients During Physiotherapy Treatment

The main objective of the study is to determine the impact of cystic fibrosis affecting a child on the parents' quality of life, their possible anxiety and depressive symptoms, their general fatigue and the feeling of burden in these caregivers.

Cystic fibrosis is the most common rare genetic disease in France, and in European countries in general. According to current epidemiological data, 80,000 people worldwide are affected. It represents a major public health issue, as it is a chronic disease that has a major impact on the life expectancy of affected patients. Thanks to the latest medical advances, promising treatments are now available, helping to improve patient survival rates to over 40-50 years. Among existing treatments, respiratory and musculoskeletal physiotherapy are highly recommended. It will play a key role throughout the life of a cystic fibrosis patient. Patients with chronic respiratory diseases are at high risk of developing anxiety and depressive symptoms. As the disease worsens, the patient becomes increasingly dependent, leading to restrictions in participation and activities of daily living. As a result, the presence of family and friends is of paramount importance in ensuring that sick children adhere to treatment and take their medication. However, this workload on the part of a parent, who has to make major changes to their lifestyle in order to adapt to their child's treatment, can have a considerable impact on their well-being, and increase the risk of anxiety/depression, even leading to burnout. Psychologists have studied the subject of assessing quality of life in parents of children with cystic fibrosis. At present, knowing that the quality of life of sufferers is as much affected as that of their caregivers, questionnaires have been introduced to assess parents' quality of life, notably the CarerQol-7D . The aim of this study would be to raise the issue of exhaustion among parents of children with cystic fibrosis, and to consider how to reduce the impact of this heavy mental burden on them. This would contribute to better therapeutic adherence and improved treatment of children. To this end, questionnaires and interviews could be set up with parents, with the aim of developing a relevant and optimal action strategy for their children.

Eligibility Criteria:
Inclusion Criteria:

* parents (father, mother, dyads (father+mother) of children suffering from cystic fibrosis) who agree to answer the various questionnaires.

Exclusion Criteria:

-
Study of the ETX-4143 2.0 Device in Subjects with Eye Pain

A prospective early-feasibility study to evaluate the safety and effectiveness of the ETX-4143 2.0 device. The device is intended to treat subjects with eye pain

A prospective early-feasibility study to evaluate the safety and effectiveness of the ETX-4143 2.0 device. The device is intended to treat subjects who suffer from eye pain an do not get relieve from current medications or clinical treatments. Thirty eyes will be enrolled and randomized 2:1 to the investigational treatment or a sham treatment. Improvement in self-reported ocular pain and clinical safety measures will be evaluated.

It is anticipated that the learnings from the study will be used to design future study of the ETX-4143 2.0 device.

All subjects will be followed for 8 weeks. Subjects will only have the worse eye treated if both eyes meet the inclusion/exclusion criteria.

A medical monitor will evaluate the safety of the study on a continual basis.

Eligibility Criteria:
Inclusion Criteria:

* Documented history of eye pain with no relief from currently available medications or treatments
* Willing to forgo participation in any other clinical stud for the duration of this study
* Demonstrate sufficient cognitive awareness to comply with the examination process
* Willing and able to comply with the schedule for follow-up visits
* Willing to participate in the study as evidenced by signing an informed consent document

Exclusion Criteria:

* Women who are pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study time period, including the follow-up period
* Any active ocular infection or active ocular inflammation at the time of the screening visit
* History of herpes keratitis, non-healing corneal epithelial defects, or neurotrophic keratopathy due to corneal herpetic disease, stem cell deficiency, diabetic keratopathy, severe lagophthalmos, or topical anesthetic abuse
* Any history of significant eye surgery with the prior 90 days
* Planned eye surgery during the entire study
* Participation in any clinical study of an investigational product within 30 days prior to enrollment
* Any history of serious, poorly controlled systemic or ophthalmic condition that could compromise the subject's ability to comply with the protocol or compromise their safety
Evaluation of Ureteral Jets on Cystoscopy

This study evaluates 4 different methods to aid surgeons to visualize ureteral jets on cystoscopy.

This study proposes to test and compare the surgeon's impression/confidence in identifying ureteral jets using 3 other methods in contrast to standard diagnostic cystoscopy: 1) cystoscopy with Dextrose 10% solution, 2) cystoscopy with phenazopyridine and 3) IV sodium fluorescein 4) standard cystoscopy with saline.

Eligibility Criteria:
Inclusion Criteria:

* adult
* undergoing a cystoscopy or as part of their planned procedure

Exclusion Criteria:

* Chronic kidney disease
* known prior surgical removal of kidney or ureteral obstruction
* Current ureteral stent placed
* Allergy to any of the interventions
Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)

This study will evaluate the safety and efficacy of RAD001 in treating patients with Angiomyolipoma associated with Tuberous Sclerosis Complex or Sporadic Lymphangioleiomyomatosis.


Eligibility Criteria:
Inclusion Criteria:

* Male or Female 18 years or older
* Clinically definite diagnosis of Tuberous Sclerosis Complex according to the modified Gomez criteria or sporadic LAM (biopsy-proven or compatible chest CT scan)
* Clinically definite diagnosis of renal angiomyolipoma
* At least one Angiomyolipoma of ≥ 3 cm in its longest diameter using CT or MRI
* Females of child bearing potential must use birth control and have documentation of negative pregnancy test
* Written informed consent according to local guidelines

Exclusion Criteria:

* Recent heart attack, cardiac related chest pain or stroke
* Severely impaired lung function
* Bleeding related to angiomyolipoma or embolization during 6 months prior to randomization
* Clinically significant chylous ascites
* Clinically significant hematological or hepatic abnormality
* Severe liver dysfunction
* Severe kidney dysfunction
* Pregnancy or breast feeding
* Current infection
* History of organ transplant
* Surgery within two months prior to study enrollment
* Prior therapy with a medication in the same class as Everolimus
* Recent use of an investigational drug
* Bleeding diathesis or on oral anti-vitamin K medication
* Uncontrolled high cholesterol
* Uncontrolled diabetes
* HIV
* Inability to attend scheduled clinic visits
* Patients with metal implants thus prohibiting MRI evaluations
* Angiomyolipoma which requires surgery at the time of randomization
* History of malignancy
* Severe or uncontrolled medical conditions which would cause an unacceptable safety risk or compromise compliance with the protocol
Use of [18]F-FDG on PET/CT as an Alternative Non-invasive Method for Staging of Lung Cancer

To evaluate the diagnostic accuracy of the 18Fluor-fluorodeoxyglucose (\[18F\]FDG) in the Positron Emission Tomography/Computed Tomography (PET/CT) as compared to mediastinoscopy for staging of non-small cel lung carcinoma.

The main aim of this study is to validate the \[18F\]FDG on PET/CT for the diagnosis of metastatic ganglions at the mediastinum in SUS patients with non-small cell lung carcinoma considering sensitivity, specificity, positive predictive value, negative predictive value, accuracy. Other specific aims are:

* Analyze the diagnosis performance of the \[18F\]FDG on PET/CT in two timepoints (1 and 2 hours after exam), in relation to the staging of the non-small cell lung carcinoma
* Evaluate the addition of the iodinated contrast in the \[18F\]FDG to improve the images obtained from the PET/CT in the staging of the non-small cell lung carcinoma

Eligibility Criteria:
Inclusion Criteria:

1. Individuals with histological diagnosis or high suspicion of non-small cell lung carcinoma
2. Patients who previously underwent staging of the disease with CT
3. Clinical stages I-III AJCC 7th edition.
4. Patients with indication for mediastinoscopy and linfonodal biopsy
5. Patients without treatment for lung cancer
6. Patients with biochemical and haematological exams
7. Women of childbearing potential using contraceptive methods and negative pregnancy test
8. Adults with more than 18 years old.
9. Both genders

Exclusion Criteria:

* Pregnant women
* Patients with other types of patients